Literature DB >> 28543414

Closed Financial Loops: When They Happen in Government, They're Called Corruption; in Medicine, They're Just a Footnote.

Kevin De Jesus-Morales, Vinay Prasad.   

Abstract

Many physicians are involved in relationships that create tension between a physician's duty to work in her patients' best interest at all times and her financial arrangement with a third party, most often a pharmaceutical manufacturer, whose primary goal is maximizing sales or profit. Despite the prevalence of this threat, in the United States and globally, the most common reaction to conflicts of interest in medicine is timid acceptance. There are few calls for conflicts of interest to be banned, and, to our knowledge, no one calls for conflicted practitioners to be reprimanded. Contrast our attitudes in medicine with public attitudes toward financial conflicts among government employees. When enforcement of rules against conflict of interest slackens in the public sector, news organizations investigate and publish their criticism. Yet even when doctors are quoted in the media promoting specific drugs, their personal financial ties to the drug maker are rarely mentioned. Policies for governmental employees are strict, condemnation is strong, and criminal statutes exist (allowing for corruption charges). Yet the evidence that conflict is problematic is, if anything, stronger in medicine than in the public sector. Policies against conflicts of interest in medicine should be at least as strong as those already existing in the public sector.
© 2017 The Hastings Center.

Entities:  

Mesh:

Year:  2017        PMID: 28543414     DOI: 10.1002/hast.700

Source DB:  PubMed          Journal:  Hastings Cent Rep        ISSN: 0093-0334            Impact factor:   2.683


  4 in total

1.  Financial Conflicts of Interest Among Oncologist Authors of Reports of Clinical Drug Trials.

Authors:  Cole Wayant; Erick Turner; Chase Meyer; Philip Sinnett; Matt Vassar
Journal:  JAMA Oncol       Date:  2018-10-01       Impact factor: 31.777

2.  Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study.

Authors:  Jeffrey Wagner; John Marquart; Julia Ruby; Austin Lammers; Sham Mailankody; Victoria Kaestner; Vinay Prasad
Journal:  BMJ       Date:  2018-03-07

3.  Is There Already a Need of Reckoning on Cancer Immunotherapy?

Authors:  Pierpaolo Correale; Francesca Pentimalli; Giovanni Baglio; Marjia Krstic-Demonacos; Rita Emilena Saladino; Antonio Giordano; Luciano Mutti
Journal:  Front Pharmacol       Date:  2021-03-26       Impact factor: 5.810

4.  National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study.

Authors:  Joel Lexchin; Sharon Batt; Devorah Goldberg; Adrienne Shnier
Journal:  BMJ Open       Date:  2022-03-09       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.